Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its key drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback